Tag Archives: doxorubicin

The patients who developed cardiotoxicity were treated with beta blockers (carvedilol), angiotensin-converting enzyme inhibitors (enalapril) or angiotensin receptor blockers (valsartan), aldosterone antagonists (eplerenone), digitalis and diuretics (furosemide), as needed. When patients remained symptomatic and met the PARADIGM-HF inclusion criteria, sacubitril/valsartan was started instead of enalapril or valsartan. Results showed that sacubitril/valsartan therapy produced an improvement in ventricular remodelling, diastolic dysfunction, and on symptoms, reflected in the New York Heart Association class and the six-minute walk test. The auth

Introduction Breast cancer is one of the major public health problems; it is the second most common cancer among women and it has a high mortality rate.1 Doxorubicin, which is an antibiotic of the anthracycline group, has a cytotoxic antineoplastic activity and is commonly used in a broad spectrum of malignancies, either alone or in combination with other drugs. Despite its usefulness in chemotherapy of breast cancer, its cardiac side effects, such as cardiomyopathy and congestive heart failure, cause considerable limitations and obstacles for oncologists and cardiologists.2,3 Doxorubicin’s cardiotoxicity is mainly due to oxidative stress,